Waldenström's macroglobulinemia other diagnostic studies: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Waldenström's macroglobulinemia}}
{{Waldenström's macroglobulinemia}}
{{CMG}} {{AE}}{{S.M.}} {{RAK}}
{{CMG}}; {{AE}} {{S.M.}}, {{RAK}}; {{GRR}} {{Nat}}


==Overview==
==Overview==

Revision as of 18:48, 8 April 2019

Waldenström's macroglobulinemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Waldenström's macroglobulinemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Bone Marrow Aspiration and Biopsy

Electrophoresis and Immunofixation

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Waldenström's macroglobulinemia other diagnostic studies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Waldenström's macroglobulinemia other diagnostic studies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Waldenström's macroglobulinemia other diagnostic studies

CDC on Waldenström's macroglobulinemia other diagnostic studies

Waldenström's macroglobulinemia other diagnostic studies in the news

Blogs on Waldenström's macroglobulinemia other diagnostic studies

Directions to Hospitals Treating Waldenström's macroglobulinemia

Risk calculators and risk factors for Waldenström's macroglobulinemia other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2], Roukoz A. Karam, M.D.[3]; Grammar Reviewer: Natalie Harpenau, B.S.[4]

Overview

Other diagnostic studies for Waldenström macroglobulinemia include nerve conduction study, electromyography, funduscopy, and plasma viscosity.

Other Diagnostic Studies

Other diagnostic studies for Waldenström macroglobulinemia include:

  • Nerve conduction study and electromyography, which demonstrates:[1]
  • Fundoscopy should be performed in all patients with symptoms of hyperviscosity and/or IgM ≥3000 mg/dL. Fundoscopic findings are as follows:[2]
  • Plasma viscosity, which demonstrates:[3]
    • Values > 1.5 centipoise
      • Should be measured in patients presenting with signs and symptoms suggestive of hyperviscosity syndrome or whenever the monoclonal IgM protein spike is > 4 g/dL.
  • Mutational analysis for the MYD88 gene, since the MYD88 L265P mutation is found in 90% of patients with Waldenstrom's macroglobulinemia[4]
  • In patients with peripheral neuropathy, other causes of neuropathy should be ruled out by performing respective tests (as required) for diabetes, cobalamin (vitamin B12) deficiency, thyroid dysfunction, and Lyme disease.

References

  1. Nobile-Orazio E, Marmiroli P, Baldini L, Spagnol G, Barbieri S, Moggio M, Polli N, Polli E, Scarlato G (1987). "Peripheral neuropathy in macroglobulinemia: incidence and antigen-specificity of M proteins". Neurology. 37 (9): 1506–14. PMID 2442666.
  2. Castillo JJ, Garcia-Sanz R, Hatjiharissi E, Kyle RA, Leleu X, McMaster M; et al. (2016). "Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia". Br J Haematol. 175 (1): 77–86. doi:10.1111/bjh.14196. PMC 5154335. PMID 27378193.
  3. Crawford J, Cox EB, Cohen HJ (1985). "Evaluation of hyperviscosity in monoclonal gammopathies". Am J Med. 79 (1): 13–22. PMID 4014299.
  4. Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X; et al. (2013). "MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction". Blood. 121 (11): 2051–8. doi:10.1182/blood-2012-09-454355. PMC 3596964. PMID 23321251.

Template:WH Template:WS